LIVE MARKET TRACKER :   BSE SENSEX   33053.04      |    NSE NIFTY 10192.95    
GLOBAL MARKETS :  NASDAQ      |    FSI London      |    NIKKEI Japan  
  USD GBP EUR CAD AUD INR
USD -
GBP -
EUR -
CAD -
AUD -
INR -
Indian-Commodity  :  Equity & Shares  :  Vista Pharma touches the roof on the BSE

Vista Pharma touches the roof on the BSE (14-Jul-2017)

Vista Pharmaceuticals is currently trading at its upper circuit limit of Rs. 32.70, up by 1.55 points or 4.98% from its previous closing of Rs. 31.15 on the BSE.

The scrip opened at Rs. 31.40 and has touched a high and low of Rs. 32.70 and Rs. 31.40 respectively. So far 63933 shares were traded on the counter.

The BSE group 'XT' stock of face value Rs. 2 has touched a 52 week high of Rs. 47.95 on 17-Apr-2017 and a 52 week low of Rs. 15.50 on 22-Nov-2016.

Last one week high and low of the scrip stood at Rs. 35.25 and Rs. 31.15 respectively. The current market cap of the company is Rs. 87.64 crore.

The promoters holding in the company stood at 31.19%, while institutions and non-institutions held 0.05% and 68.75% respectively.

Vista Pharmaceuticals has received a warning letter from the US Food & Drug Administration (USFDA) for significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals at its formulation plant located at Nalgonda district in Telangana. The US regulator had inspected the said plant from September 19 to 23, 2016 and issued Form 483 observations.

Vista Pharmaceuticals is engaged in manufacturing and selling of pharmaceutical, medical and veterinary preparations. The company also sells the products to its related companies, which are engaged in the manufacture of formulations.


Top News Today
Talwalkars commences construction of first leisure club in Pune
(13-Dec-2017)

Talwalkars commences construction of first leisure club in PuneTalwalkars Better Value Fitness has commenced the construction of its first leisure club in Wakad, Pune. Post the compliance of various statutory procedures, the club project has received necessary sanctions......click on news to read complete article.

NIIT features in '2017 Top 20 IT Training Company' list
(13-Dec-2017)

NIIT features in NIIT has been featured by Training Industry among 2017 Top 20 IT Training Company for the eighth consecutive year. Training Industry is one of the most trusted sources of information on the business of......click on news to read complete article.

Orchid Pharma receives ANDA approval for Aripiprazole Orally-Disintegrating Tablets
(13-Dec-2017)

Orchid Pharma receives ANDA approval for Aripiprazole Orally-Disintegrating TabletsOrchid Pharma has received ANDA approval from USFDA for Aripiprazole Orally-Disintegrating Tablets USP, 10 mg and 15 mg. Aripiprazole Orally-Disintegrating Tablets are atypical antipsychotic, indicated......click on news to read complete article.

International Stock News
US markets closed higher on Monday
(12-Dec-2017)

US markets closed higher on MondayThe US markets closed higher on Monday, with the S&P 500 index and Dow industrials closing at records on the back of a rally in telecommunications and technology shares. Wall Street shrugged off......click on news to read complete article.

Asian markets trade higher in early deals on Monday
(11-Dec-2017)

Asian markets trade higher in early deals on MondayAsian equity benchmark indices are trading higher in the early deals on Monday, lifted by encouraging employment data from the US that took the Standard & Poor's 500 Index to its third straight......click on news to read complete article.

US markets end at record highs on upbeat jobs data
(09-Dec-2017)

US markets end at record highs on upbeat jobs dataThe US markets traded with traction and ended near record high levels on Friday, as traders reacted positively to the closely watched monthly jobs report. The continued advance by stocks came following......click on news to read complete article.

 

     
  
Recent Equity & Shares News
 
EquityInvestmentCompany ReportsIPO
Disclaimer
By clicking on this page you accept all the terms and conditions framed by us. News made available here are for informational purpose only. While utmost care has been taken in providing the same. We claim no responsibility for its accuracy. Readers of this blog who make their decision based on the information posted here are solely responsible for their actions.